Zheng Siting, Li Sheng, Tang Shunli, Pan Yunlei, Ding Yuwei, Qiao Jianjun, Fang Hong
Department of Dermatology, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Front Med (Lausanne). 2020 Feb 18;7:20. doi: 10.3389/fmed.2020.00020. eCollection 2020.
Sweet syndrome is a neutrophilic dermatosis that could be associated with malignancy, especially hematologic malignancy. Few studies have systematically elaborated on this disorder and its features related with hematologic malignancy. This study aimed to describe the clinicopathological characteristics, treatment, and outcome of Sweet syndrome and to evaluate patient characteristics associated with hematologic malignancy. We retrospectively reviewed patients with Sweet syndrome at the Department of Dermatology, the First Affiliated Hospital of Zhejiang University from October 2010 to February 2019. The study included 37 patients (16 men and 21 women), with a mean age of 53 years. Ten patients (27%) were classified as having malignancy-associated Sweet syndrome: nine with a hematologic malignancy including acute myeloid leukemia (4/9, 44%), myelodysplastic syndrome (4/9, 44%), and multiple myeloma (1/9, 11%) and one with a solid tumor diagnosed with liver carcinoma. The mean hemoglobin and platelet levels ( = 0.007 and = 0.013, respectively), were significantly lower in patients with hematologic malignancy than in those with Sweet syndrome only. No significant difference in histopathology was found between patients with and without hematologic malignancy. Systemic corticosteroids were the most frequently used treatment (24/37, 65%). Higher mortality was found in patients with hematologic malignancy. It is important to assess Sweet syndrome patients who have laboratory evidence of lower hemoglobin and platelet levels for a hematologic malignancy.
Sweet综合征是一种中性粒细胞性皮肤病，可能与恶性肿瘤相关，尤其是血液系统恶性肿瘤。很少有研究系统阐述这种疾病及其与血液系统恶性肿瘤相关的特征。本研究旨在描述Sweet综合征的临床病理特征、治疗及预后，并评估与血液系统恶性肿瘤相关的患者特征。我们回顾性分析了2010年10月至2019年2月浙江大学医学院附属第一医院皮肤科收治的Sweet综合征患者。该研究纳入了37例患者（16例男性和21例女性），平均年龄53岁。10例患者（27%）被归类为恶性肿瘤相关的Sweet综合征：9例患有血液系统恶性肿瘤，包括急性髓系白血病（4/9，44%）、骨髓增生异常综合征（4/9，44%）和多发性骨髓瘤（1/9，11%），1例患有实体肿瘤，诊断为肝癌。血液系统恶性肿瘤患者的平均血红蛋白和血小板水平（分别为 = 0.007和 = 0.013）显著低于单纯Sweet综合征患者。有或无血液系统恶性肿瘤的患者在组织病理学上无显著差异。全身使用糖皮质激素是最常用的治疗方法（24/37，65%）。血液系统恶性肿瘤患者的死亡率更高。对血红蛋白和血小板水平较低且有实验室证据的Sweet综合征患者评估是否存在血液系统恶性肿瘤很重要。
